Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at α7* nicotinic receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 48-58

  Lopes, Cristiane ^a   Pereira, Edna F R ^a   Wu, Hui Qiu ^a   Purushottamachar, Puranik ^a   Njar, Vincent ^a   Schwarcz, Robert ^a   Albuquerque, Edson X ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ATROPINE; BUNGAROTOXIN RECEPTOR; CHOLINE; DOPAMINE; GALANTAMINE; GLUTAMATE RECEPTOR ANTAGONIST; KYNURENIC ACID; TETRODOTOXIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG POTENTIATION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE; WHOLE CELL;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; ATROPINE; CELLS, CULTURED; CHOLINE; CORPUS STRIATUM; DOPAMINE; GALANTAMINE; KYNURENIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 34250716453     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123109     Document Type: Article

References (48)

1. Alkondon M, Pereira EFR, Yu P, Arruda EZ, Almeida LE, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, et al. (2004) Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via α7 nicotinic receptors in the hippocampus. J Neurosci 24:4635-4648.
2. Alkondon M, Reinhardt S, Lobron C, Hermsen B, Maelicke A, and Albuquerque EX (1994) Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptor subunits by in situ hybridization. J Pharmacol Exp Ther 271:494-506.
3. Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villarroya M, Garcia AG, and Lopez MG (2004) Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46:103-114.
4. Auld DS, Kornecook TJ, Bastianetto S, and Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209-245.
5. Baran H, Jellinger K, and Deecke L (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106:165-181.
6. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr., Davis L, et al. (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277:728-738.
7. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, Clementi F, Moretti M, Rossi FM, Le Novere N, et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knockout mice. J Neurosci 23:7820-7829.
8. Chess AC and Bucci DJ (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 170:326-332.
9. Corey-Bloom J (2003) Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract 57:219-223.
10. 2+ signals and neurotransmitter release. Mol Pharmacol 64:1217-1226.
11. Dajas-Bailador F and Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 25:317-324.
12. Dani JA, De Biasi M, Liang Y, Peterson J, Zhang L, Zhang T, and Zhou FM (2004) Potential applications of nicotinic ligands in the laboratory and clinic. Bioorg Med Chem Lett 14:1837-1839.
13. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, Tsuang MT, Farone SV, Malaspina D, Svrakic DM, et al. (2001) Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the α7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 105:20-22.
14. Gahring LC and Rogers SW (2006) Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J 7:E885-E894.
15. Grilli M, Raiteri L, Patti L, Parodi M, Robino F, Raiteri M, and Marchi M (2006) Modulation of the function of presynaptic α7 and non-α7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br J Pharmacol 149:724-732.
16. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, and Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473.
17. Hume JR and Leblanc RN (1988) A whole-cell patch clamp technique which minimizes cell dialysis. Mol Cell Biochem 80:49-57.
18. Jann MW, Shirley KL, and Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719-739.
19. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, and Shimohama S (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun 325:976-982.
20. Krauss M, Korr D, Herrmann A, and Hucho F (2000) Binding properties of agonists and antagonists to distinct allosteric states of the nicotinic acetylcholine receptor are incompatible with a concerted model. J Biol Chem 275:30196-30201.
21. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, et al. (2002) Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59:1085-1096.
22. Levin ED, McClernon FJ, and Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184:523-539.
23. Lindstrom JM (2003) Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 998:441-452.
24. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397-401.
25. Luntz-Leybman V, Bickford PC, and Freedman R (1992) Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587:130-136.
26. Maelicke A and Albquerque EX (1996) New approach to drug therapy in Alzheimer's dementia. Drug Disc Today 1:53-59.
27. Mazeh D, Zemishlani H, Barak Y, Mirecki I, and Paleacu D (2006) Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int Psychogeriatr 18:429-436.
28. Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, and Jovovich V (1989) Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 39:50-58.
29. Mike A, Castro NG, and Albuquerque EX (2000) Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neurons. Brain Res 882:155-168.
30. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49:200-210.
31. Norén U, Bjorner A, Sonesson O, and Eriksson L (2006) Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res 85:302-304.
32. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, and Saso S (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42:1702-1706.
33. Pereira EFR, Hilmas C, Santos MD, Alkondon M, Maelicke A, and Albuquerque EX (2002) Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53:479-500.
34. Rangwala F, Drisdel RC, Rakhilin S, Ko E, Atluri P, Harkins AB, Fox AP, Salman SS, and Green WN (1997) Neuronal α-bungarotoxin receptors differ structurally from other nicotinic acetylcholine receptors. J Neurosci 17:8201-8212.
35. Rassoulpour A, Wu HQ, Ferré S, and Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 93:762-765.
36. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, and Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
37. Schubert MH, Young KA, and Hicks PB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530-533.
38. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, and Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530.
39. Sharma T, Reed C, Aasen I, and Kumari V (2006) Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 85:73-83.
40. Shepard PD, Joy B, Clerkin L, and Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28:1454-1462.
41. Singh A, Potter A, and Newhouse P (2004) Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs 7:1096-1103.
42. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309-379.
43. Tariot PN (2006) Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. J Clin Psychiatry 67:15-22.
44. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, and Schwarcz R (1988) Identification and quantification of kynurenic acid in human brain tissue. Brain Res 454:164-169.
45. Wu HQ, Ungerstedt U, and Schwarcz R (1992) Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats. Eur J Pharmacol 213:375-380.
46. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, and Sharkey J (2007) Impaired attention is central to the cognitive deficits observed in α7 deficient mice. Eur Neuropsychopharmacol 17:145-155.
47. Zhang L, Zhou FM, and Dani JA (2004) Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 66:538-544.
48. Zwart R and Vijverberg HP (1997) Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol 52:886-895.